Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, and Interim Editor in Chief Nielsen Hobbs discuss the implications of the BIOSECURE Act on the pharma industry in the US and China, as well as other hot topics.
It seems like there’s a lot of level setting the FDA and Congress are going to have to do here.
Related products